"Pharmaceutical Speed Reader" Amjin Enbrel patent won the case of 9 drugs discontinued, recalled.

the National Drug Administration: 9 drugs discontinued, recalled; Amgen Enbrel patent winning U.Smarket exclusive period extended to 2029; Sanofi/Regenerative Kevzara treatment phase III clinical failure; Sarepta reached a $400 million partnership to obtain exclusive global license for DMD gene therapy ..3, in the municipal government press office held the 140th routine press conference on the prevention and control of the outbreak, the relevant person in charge of the Beijing Municipal Public Security Bureau informed that, from 0:00 on July 4, the city's low-risk areas of personnel out of Beijing, no longer require the holding of nucleic acid testing negative certificate(Beijing Municipal Government Information Office)2, the State Drug Administration issued circular No45 of 2020, informed 10 batches of non-compliant drugsThe notice pointed out that by the Jiangxi Province Drug Inspection and Testing Research Institute and other 9 drug inspection institutions, marked as Chengdu Jinhua Pharmaceutical Co., Ltdand other 10 enterprises produced 10 batches of drugs do not comply with the regulations, involving pyrethyl amide tablets, lansola intestinal tablets, injection of inflammatory amber, chai yellow particles, clear-eye tablets, viheinn particles, guangfen, yellow essence, Qin Qi(State Drug Administration)Yunnan Provincial Medical Insurance Bureau issued on the 1st", "Yunnan Province super-national medical insurance drug catalog scope drug digestion adjustment program" notice, according to the notice, from June 30, 2020, 24 hours, synchronously transferred drugs from the 2019 edition of the National Drug Catalog, drugs that exceed the state medical insurance payment form, compound drugs, the state explicitly do not pay chinese medicine tablets, state key monitoring and drug reimbursementYunnan Province, a total of 837 drugs in the super-national medical insurance catalogue, including 416 Western medicine and 421 traditional Chinese medicine(Yunnan Provincial Health Insurance Bureau)local time on July 2, Amin won the U.SCourt of Appeals for Enbrel patent case, the court upheld Enbrel patent extension to 2029According to the ruling, the anti-inflammatory drug will enjoy a 31-year market advantage in the U.SmarketAmin's shares rose 8 per cent to $255.12 at the close of trading on July 2 (Sina Pharmaceutical News) Sarepta Therapeutics has announced an agreement with Hansa Biopharma to obtain an exclusive global license to develop and promote imlifidase as a pre-treatment to expand the use of gene therapy for Du's muscular dystrophy (DMD) and limb-belt muscular dystrophy (LGMD) Imlifidase is a protease that cuts off IgG antibodies (Pharmaceutical Mingkang) july 2 local time, Sanofi and Regenerative Yuan announced the results of The third phase of Kevzara's treatment of COVID-19 The results showed that in patients with COVID-19 severe illness who required mechanical ventilation, the Combination of Kevzara 400mg and the best supportive treatment did not reach the primary and secondary endpoints compared to the best supported treatment alone (Sina Pharmaceutical News) Ipson recently announced the positive results of a Phase I/II study on the treatment of pancreatic cancer by Onivyde plus chemotherapy The best total mitigation rate (BOR) was 1 full remission (CR, diagnosed as local late stage III disease), 3% (1/32), 10 partial remission (PR), 31.3% (10/32), 15 stable diseases (SD), and 46.9% (15/32) BOR (CR-PR-SD) was 81.4% (Bio Valley) the U.S FDA announced approval for the listing of The Rukobia (fostemsavir), developed by ViiV Healthcare This is a new type of antiretroviral drug for HIV-infected people who have tried multiple HIV treatments and have not been successfully treated due to drug resistance, intolerance or safety , Johnson and Johnson's sugar drug Invokana (canagliflozin, kagresnet) was approved in the European Union for the treatment of diabetic nephropathy (DKD) in patients with type 2 diabetes (T2D), and its drug labels will include important kidney prognostic data from the landmark CREDENCE trial In Europe, Invokana is the first drug approved for use in T2D patients to slow the progression of DKD, and the only SGLT2 inhibitor approved for use in the treatment of DKD in T2D patients (Sina Pharmaceutical News) 2, Hengrui announced that its class 1 new drug SHR0302 alkali ointment approved for white wind clinical trials According to the Hengrui announcement, the SHR0302 project has accumulated research and development costs of about 173 million yuan (Pharma Rubik's Cube) China Biopharmaceuticals announced that its subsidiary Nanjing Zhengda Qing 4 class of generic drug sulphate clopipidogrel tablets (commodity name: Uliwei) approved the listing of the State Drug Administration, as through the consistency evaluation, as the fourth in China (Pharma Rubik's Cube)